domingo, 10 de noviembre de 2019

AI in drug development: the FDA needs to set standards - STAT

AI in drug development: the FDA needs to set standards - STAT

First Opinion

The FDA needs to set standards for using artificial intelligence in drug development

By CHARLES K. FISHER


DOM SMITH/STAT
As companies apply artificial intelligence to drug development and clinical trials, FDA standards would ease regulatory uncertainty.

No hay comentarios: